hemady®
(dexamethasone) tablets 20 mg

*Hemady® is a corticosteroid indicated in combination with other antimyeloma products for the treatment of adults with multiple myeloma[1]

The first and only FDA-approved dexamethasone tablet specifically indicated for multiple myeloma*

HEMADY® reduces up to

80%

of the number of tablets required for a therapeutic dose of dexamethasone for the treatment of adults with MM[1]

Hemady® is a unique strength dexamethasone tablet bioequivalent to five 4 mg tablets of dexamethasone[1]

76%

According to a physician survey, 76% of multiple myeloma patients are prescribed dexamethasone therapy[3]

REAL-WORLD COMPARISON OF ADHERENCE
to Hemady® and generic dexamethasone among patients with MM[2]

Adherence	Cohort 1: Dex 4 mg Only		Cohort 2: Hemady® Only		Cohort 1 vs Cohort 2
Total, n	3775		43		
Medication Possession Ratio (MPR)					
Overall					
mean (SD)	89.5%	(16.2%)	97.1%	(12.0%)	**P = 0.0002**
lower, upper (95% CL for mean)	89.0%	90.0%	93.4%	100.8%	
% of Adherent Patients (MPR ≥ 80%)					
Overall	78.4%		95.3%		**P = 0.007**

Dex: dexamethasone. MM: multiple myeloma.

Retrospective analysis to quantify and compare adherence of Hemady and generic dexamethasone among MM patients using real-world evidence[2]

Edenbridge Pharmaceuticals

References: 1. Hemady [Prescribing Information], Edenbridge Pharmaceuticals, LLC. June 2023. 2. Data on file (Adherence Study Results). Edenbridge Pharmaceuticals, LLC. 2023. 3. Data on file (Physician Survey Results). Edenbridge Pharmaceuticals, LLC. 2023.